Pauline has about 30 years’ experience in helping to maximise the translation of early-stage research in the life sciences into health benefits for patients and the creation of commercial income.

Her first degree in microbiology at UCL and PhD in cell biology at UCL and the Imperial Cancer Research Fund were followed by a research career in viral gene regulation at Stanford University and developing viral-like proteins as a therapeutic model for HIV at British Biotechnology, Oxford.

She made the transition to technology transfer at the Ludwig Institute for Cancer Research followed by LifeArc (formerly MRC Technology) in order to fulfill a desire to support the translation of novel and ground-breaking science eventually into new drugs and diagnostics.

After a secondment at Albion Capital and UCL Business to work with the UCL Technology Fund team she returned to LifeArc as Investment Principal in LifeArc’s Seed Fund, seeking out and supporting investment in early-stage biotech companies developing novel therapeutic drugs. She championed and secured investment of >£5m for four early-stage companies and sat as NED on their boards. One of these companies, DJS Antibodies was recently acquired by Abbvie for $255m.